GATC Health Welcomes Former U.S. Counselor of Embassy William Steuer to Its Advisory Board

Irvine, CA – April 3, 2025 – GATC Health Corp., a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, welcomes William Steuer to its Board of Advisors. William Steuer is a retired career member of the U.S. Department of State’s Senior Foreign Service and will serve as GATC Health’s International Trade Advisor, aiding with the expansion of the company’s interests overseas.

Mr. Steuer brings decades of expertise in diplomacy, cross-cultural engagement, management, and high-stakes negotiations to the corporate arena. As a former Counselor of Embassy, Steuer served in leadership roles equivalent to Chief Executive and Chief Operations Officer at some of the United States' largest and most strategic embassies across Africa, Central Asia, and the Middle East.

“As we move to share our groundbreaking AI platform globally, it’s imperative that GATC recruit and retain recognized leaders in their fields to help us navigate this period of tremendous growth,” stated John Stroh, CEO of GATC Health. “Will Steuer is a seasoned diplomatic professional of the highest caliber, who can represent GATC’s interests to potential foreign customers, investors, and partners with strategic precision and diplomatic expertise. Will is a brilliant statesman and a tremendous asset to our company.”

Throughout his distinguished career, Steuer cultivated an extensive network of contacts across federal government agencies and the international business community. His deep understanding of global affairs and cross-border operations equips him to address a broad spectrum of topics including foreign investment strategy, geopolitical and cultural insights, negotiation tactics, contract review, immigration frameworks, and foreign education initiatives.

“GATC's innovative and exciting approach to accelerating drug development has significant potential for many diverse global applications," stated Steuer. "From optimizing capital allocation in drug development to exploring novel insurance and finance products with Lloyd’s of London, MCI and Acrisure, GATC's technology offers substantial value across multiple sectors. There are many opportunities with GATC that can allow foreign investment and joint research to be part of this transformative process. We look forward to exploring these possibilities with potential partners around the world.”

About GATC Health

GATC Health Corp. is a tech-bio company transforming drug discovery and development through its AI-driven platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.

For more information, visit www.gatchealth.com.